Compare RLMD & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLMD | RPD |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.6M | 780.5M |
| IPO Year | 2012 | 2015 |
| Metric | RLMD | RPD |
|---|---|---|
| Price | $7.07 | $6.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 21 |
| Target Price | $12.40 | ★ $15.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | $13,070.00 | ★ $685,083,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.54 |
| P/E Ratio | ★ N/A | $17.57 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.27 | $4.97 |
| 52 Week High | $7.94 | $27.10 |
| Indicator | RLMD | RPD |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 54.83 |
| Support Level | $3.49 | $5.92 |
| Resistance Level | $7.41 | $7.17 |
| Average True Range (ATR) | 0.44 | 0.41 |
| MACD | -0.07 | 0.19 |
| Stochastic Oscillator | 35.01 | 75.58 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.